이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sichuan Kelun Pharmaceutical 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sichuan Liu

최고 경영자

CN¥4.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	15.1yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	8.5yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO

Sichuan Liu (40 yo)

15.1yrs

테뉴어

CN¥4,800,000

보상

Mr. Sichuan Liu has been a Director of Sichuan Kelun Pharmaceutical Co., Ltd. since June 26, 2009 and serves as its General Manager. He is a Non-Executive Director of Sichuan Kelun-Biotech Biopharmaceutica...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sichuan Liu	GM & Director	no data	CN¥4.80m	0.52% CN¥ 251.9m
Degui Lai	CFO & Deputy GM	9.8yrs	CN¥3.00m	0.033% CN¥ 15.9m
Zhonghua Wu	Deputy General Manager	8.5yrs	CN¥2.89m	0.010% CN¥ 5.0m
Wendi Fan	Deputy General Manager	2.3yrs	CN¥3.10m	0.0094% CN¥ 4.5m
Junyou Ge	Deputy GM & Director	no data	CN¥134.60k	데이터 없음
Hao Feng	Deputy GM & Secretary of the Board of Directors	13.3yrs	CN¥3.00m	0.032% CN¥ 15.4m
Deguang Chen	Officer	no data	CN¥700.00k	데이터 없음
Tan Hongbo	Deputy General Manager	11.1yrs	CN¥3.00m	0.017% CN¥ 8.0m
Tao Ge	Deputy General Manager	9.4yrs	CN¥3.00m	0.011% CN¥ 5.4m
Nanchao Ding	Deputy General Manager	4.3yrs	CN¥2.40m	데이터 없음
Yihong Liao	Deputy General Manager	2.3yrs	CN¥1.65m	0.0076% CN¥ 3.7m
Liang Wang	Deputy General Manager	2.3yrs	CN¥900.00k	0.0031% CN¥ 1.5m

8.5yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 002422 의 관리팀은 노련하고 경험 (평균 재직 기간 8.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sichuan Liu	GM & Director	15.1yrs	CN¥4.80m	0.52% CN¥ 251.9m
Junyou Ge	Deputy GM & Director	less than a year	CN¥134.60k	데이터 없음
Gexin Liu	Chairman of the Board of Directors	no data	CN¥2.00m	23.83% CN¥ 11.4b
Guosheng He	Non Independent Director	5.3yrs	CN¥100.00k	데이터 없음
Changyan Zheng	Employee-Representative Member of the Board of Supervisors	16.2yrs	데이터 없음	0.0039% CN¥ 1.9m
Jinbo Gao	Independent Director	3.1yrs	CN¥100.00k	데이터 없음
Guangji Wang	Non Independent Director	10.2yrs	CN¥100.00k	데이터 없음
Fuqing Wang	Director	less than a year	데이터 없음	데이터 없음
Wan Peng	Chairman of Board of Supervisors	9.3yrs	데이터 없음	0.00063% CN¥ 302.5k
Jinbo Gao		3.1yrs	데이터 없음	데이터 없음
Shichi Ren	Independent Director	3.1yrs	CN¥100.00k	데이터 없음
Xianxiang Zhou	Director	less than a year	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 002422 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Sichuan Kelun Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

High number of new directors

High number of new directors

High number of new directors

Sichuan Kelun Pharmaceutical Co., Ltd., Annual General Meeting, May 05, 2022

Recent updates

Sichuan Kelun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.67 (vs CN¥0.57 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.69 (vs CN¥1.22 in FY 2022)

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.38 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.43 in 2Q 2022)

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings released: EPS: CN¥1.22 (vs CN¥0.78 in FY 2021)

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.38 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

High number of new directors

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.23 in 2Q 2021)

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Final Distribution for the Year 2021, Payable on 16 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 1Q 2021)

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) announces an Equity Buyback for CNY 200 million worth of its shares.

High number of new directors

Sichuan Kelun Pharmaceutical Co., Ltd., Annual General Meeting, May 05, 2022

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.58 in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.10 in 2Q 2020)

Sichuan Kelun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 3 billion in funding

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.58 (vs CN¥0.66 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥21.88

New 90-day low: CN¥18.06

New 90-day low: CN¥20.47

New 90-day low: CN¥21.62

Revenue misses expectations

Third quarter earnings released

Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) entered into an agreement to acquire Shanghai Century Acquisition Corporation (Amex: SHA) in a reverse merger transaction.

First half earnings released

New 90-day high - CN¥25.76

Sichuan Kelun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

New 90-day high - CN¥23.83

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령